ESTIMATION OF SERUM FERROPORTIN AND LIVER ENZYMES IN BREAST CANCER PATIENTS

Breast cancer (BC) is a common malignancy and a major cause of death in women. We sought to evaluate ferroportin plasma concentration in patients with BC. A total of 90 subjects (60 BC versus 30 control healthy) enrolled in the present study. Blood sample withdrawn and serum separated for measurement of total serum bilirubin (TSB), Aspartate Transaminase (AST), alanine transaminase (ALT), ferroportin (FPN). Results: A non-significant (p<0.852) differences exists between the level TSB in BC group (0.665±0.365) compared to control group (0.654±0.191mg/dl). AST in BC group (40.1±36.0) has shown a highly significant (p>0.001) difference comparing with the control group (22.5±14.2 U/L). ALT in BC group (29.7±26.7) has shown a highly significant (p>0.004) difference comparing with the control group (18.19±9.51U/L). FPN (ng/mL) in BC group (2.47±1.59) has shown a highly significant (p>0.002) difference comparing with the control group (4.44±1.20). Conclusion: the study concluded that breast cancer was associated with elevated AST, and ALT with reduced FPN and no changes reported with TSB levels.